We are live on ! Find out more
CDTX

Cidara Therapeutics
CDTX

Delisted

CDTX was delisted on the 6th of January, 2026.

Back to rankings

54 hedge funds and large institutions have $83.6M invested in Cidara Therapeutics in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 54 → 54 (0)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 21

0.09% less ownership

Funds ownership: 3.41% → 3.31% (-0.09%)

6% less capital invested

Capital invested by funds: $89.3M → $83.6M (-$5.72M)

17% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 12

Holders
54
Holders Change
–
Holders Change %
0%
% of All Funds
1.35%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
21
Increased
10
Reduced
12
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.58M
2
BC
Broadfin Capital
New York
+$1.75M
3
PVI
Pura Vida Investments
New York
+$1.04M
4
GC
Guggenheim Capital
Illinois
+$982K
5
Renaissance Technologies
Renaissance Technologies
New York
+$691K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$5.28M
2
BlackRock
BlackRock
New York
-$3.68M
3
State Street
State Street
Massachusetts
-$970K
4
OM
Opaleye Management
Massachusetts
-$955K
5
Northern Trust
Northern Trust
Illinois
-$652K

CDTX Hedge Fund Activity: Q2 2017 in Review

54 of the 3,990 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2017, worth a combined $83.6M — down 6.4% from $89.3M a quarter earlier.

Fund positioning in CDTX was balanced in Q2 2017: 21 funds opened new positions, 21 closed out, 10 added to existing stakes and 12 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.58M. The largest seller was Perceptive Advisors, cutting an estimated $5.28M.

  • 54 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $83.6M of Cidara Therapeutics stock for Q2 2017, down 6.4% quarter-over-quarter.
  • 21 funds opened new Cidara Therapeutics positions in Q2 2017 and 21 closed out, a net change of 0 holders.
  • The largest Cidara Therapeutics buyer in Q2 2017 was Millennium Management, an estimated $2.58M added.
  • The largest Cidara Therapeutics seller in Q2 2017 was Perceptive Advisors, an estimated $5.28M sold.

Based on aggregated 13F filings for Q2 2017.